These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 26827693)

  • 21. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
    Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
    Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
    Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
    Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
    Duvic M; Vu J
    Expert Opin Investig Drugs; 2007 Jul; 16(7):1111-20. PubMed ID: 17594194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
    Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
    Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
    Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
    Thurn KT; Thomas S; Moore A; Munster PN
    Future Oncol; 2011 Feb; 7(2):263-83. PubMed ID: 21345145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Romidepsin: a novel histone deacetylase inhibitor for cancer.
    Bertino EM; Otterson GA
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vorinostat in cutaneous T-cell lymphoma.
    Duvic M; Vu J
    Drugs Today (Barc); 2007 Sep; 43(9):585-99. PubMed ID: 17940636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
    Bezecny P
    Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition.
    King K; Hauser AT; Melesina J; Sippl W; Jung M
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29393896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
    Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
    Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC inhibitor-based therapies and haematological malignancy.
    Stimson L; Wood V; Khan O; Fotheringham S; La Thangue NB
    Ann Oncol; 2009 Aug; 20(8):1293-302. PubMed ID: 19515748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
    Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
    J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
    Giannini G; Cabri W; Fattorusso C; Rodriquez M
    Future Med Chem; 2012 Jul; 4(11):1439-60. PubMed ID: 22857533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitors: biology and mechanism of action.
    Mehnert JM; Kelly WK
    Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.